(MedPage Today) – The Food and Drug Administration was granted on Wednesday the approval of acceleration on LINVOSELTAB (Lynozyfic) for multiple or thermal metal relapse after at least four previous lines of treatment. BCMA ripeness-bi-trial is a specific anti-trial object …
